FDA “Safety First” Implementation: Drug Review, Drug Safety Offices To Meet Regularly
This article was originally published in The Pink Sheet Daily
Executive Summary
Topics of discussion for joint meetings will range from broad regulatory questions to specific issues about an NDA or BLA.